Can LSIL be CIN3?

Can LSIL be CIN3?

Can LSIL be CIN3?

The risk of CIN3 following LSIL Pap at age 21–24 was 2.44% (95%CI = 1.83%–3.18%). The risk of CIN3 (n = 100) for a HPV-positive ASC-US or LSIL smear (n = 3,795 women age 21–24) was 2.63% (95%CI = 2.15%–3.20%).

Can you have CIN 3 and cancer?

Women with CIN3 have a long-lasting twofold increased risk of developing cervical cancer. The majority of women who developed cervical cancer after CIN3 were compliant to the post-treatment follow-up program. The risk of cervical cancer increases with CIN3 diagnosis at older age and further ageing during follow-up.

Does LSIL lead to cervical cancer?

LSIL often resolves on its own or can be effectively treated to help prevent development of cervical cancer. Although LSIL is not cancer, regular (and follow-up, if needed) Pap screenings are important in order to identify and treat abnormal cells before they become cancerous.

What is the difference between CIN and LSIL?

CIN is graded on a scale of 1 to 3, based on how abnormal the cells look under a microscope and how much of the cervical tissue is affected. LSIL (also called low-grade squamous intraepithelial lesion, or mild dysplasia) seen on a Pap test is generally CIN 1.

Is CIN 3 the same as carcinoma in situ?

CIN 3 means the full thickness of the cervical surface layer is affected by abnormal cells. CIN 3 is also called carcinoma-in-situ. This sounds like cancer, but CIN 3 is not cervical cancer. Cancer develops when the deeper layers of the cervix are affected by abnormal cells.

How serious is CIN3?

CIN 3 is not cancer, but may become cancer and spread to nearby normal tissue if not treated. Treatment for CIN 3 may include cryotherapy, laser therapy, loop electrosurgical procedure (LEEP), or cone biopsy to remove or destroy the abnormal tissue. CIN 3 is sometimes called high-grade or severe dysplasia.

What percentage of LSIL is cancer?

The overall risk of cancer in patients with LSIL is less than one percent.

How long does it take LSIL to become cancer?

Mean times to progression from LSIL to HSIL or cancer for women with oncogenic HPV infections were 68.4 months in women aged 31–65 years and 75.6 months in women aged 16–30 years (difference = 7.2 months, 95% CI = –9.8 to 24.2 months).